Does Strepsils® With Lignocaine Lozenges Reduce Post Operative Sore Throat Due To Supraglottic Airway Devices (POSTrepsils)
Primary Purpose
Sore Throat, Post Operative Sore Throat
Status
Completed
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Strepsils Anaesthetic Formula
Clear Mint Drops
Sponsored by
About this trial
This is an interventional prevention trial for Sore Throat focused on measuring Post operative sore throat, Post operative dysphagia, Post operative dysphonia
Eligibility Criteria
Inclusion Criteria:
- Greater than 18 years of age
- American Society of Anesthesiologists Class I-II
- Supraglottic Airway Device usage duration < 2 hours
Exclusion Criteria:
- History of upper respiratory tract infection, sore throat, dysphonia, or dysphagia in the past 2 weeks
- Morbidly obese (body mass index >35 kg/m2)
- Increased risk of regurgitation or aspiration (eg. symptomatic gastro-oesophageal reflux, hiatus hernia)
- Pregnant or nursing
- Known allergies to study drug
- More than one attempt at Supraglottic Airway Device insertion or use of adjuncts during insertion
- Insertion/presence of a gastric tube
- Expected airway difficulties or conversion to endotracheal tube
Sites / Locations
- University Malaya Medical Centre
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Strepsils
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Incidence of sore throat
Presence of sore throat defined as constant pain, independent of swallowing
Incidence of sore throat
Presence of sore throat defined as constant pain, independent of swallowing
Secondary Outcome Measures
Severity of sorethroat
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Severity of sorethroat
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Incidence of dysphagia
Presence of dysphagia defined as difficulty or pain provoked by swallowing
Incidence of dysphagia
Presence of dysphagia defined as difficulty or pain provoked by swallowing
Incidence of dysphonia
Presence of dysphonia defined as difficulty or pain on speaking
Incidence of dysphonia
Presence of dysphonia defined as difficulty or pain on speaking
Severity of dysphagia
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Severity of dysphagia
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Severity of dysphonia
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Severity of dysphonia
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Adverse effects of study drug
Any untoward medical occurrence in a subject administered an investigational product and which does not necessarily have a causal relationship with treatment.
Adverse effects of study drug
Any untoward medical occurrence in a subject administered an investigational product and which does not necessarily have a causal relationship with treatment.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03944655
Brief Title
Does Strepsils® With Lignocaine Lozenges Reduce Post Operative Sore Throat Due To Supraglottic Airway Devices
Acronym
POSTrepsils
Official Title
Does Strepsils® With Lignocaine Lozenges Reduce Post Operative Sore Throat Due To Supraglottic Airway Devices
Study Type
Interventional
2. Study Status
Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
January 17, 2019 (Actual)
Primary Completion Date
August 31, 2019 (Actual)
Study Completion Date
August 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dr Sebastian Sundaraj
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to assess the effect of preoperative administration of oral Strepsils® with added Lignocaine lozenges on the incidence of postoperative sore throat (POST) after general anaesthesia using a Supraglottic Airway Device (SAD).
Patients undergoing surgery with general anaesthesia will require ventilation of their lungs with either a flexible tube placed beyond the voice box called an endotracheal tube (ETT) or a tube placed above the voice box called a Supraglottic Airway Device. This tube helps oxygenate the patient and delivers anaesthetic gas to the lungs.
The procedure is invasive and uncomfortable, and one of the most common complaints is a sore and inflamed throat after the tube is taken out. This is termed postoperative sore throat (POST). The incidence of POST after SAD is comparable with the ETT and though many studies have focused on ETT, few have examined the SAD.
After written informed consent is received in pre-op, a sealed and coded envelope with either the Strepsils lozenges or the placebo lozenges will be given to the patient to be administered orally, with the instruction to dissolve the lozenge by sucking on it 45 minutes prior to surgery. Upon completion of surgery and emergence from general anaesthesia, the patient will be assessed regarding the incidence and severity of sore throat, difficulty in swallowing and difficulty in speaking by the investigator using an interview format. The severity of these symptoms will be graded on a 4-point scale ranging from 0 to 3; 0 being no symptoms, 1 being mild symptoms, 2 being moderate symptoms, and 3 being severe symptoms. This evaluation will be performed at 30 minutes and 24 hours post removal of SAD.
Detailed Description
The incidence of postoperative sore throat (POST) has been reported up to 62% following general anaesthesia with varying severity from mild to severe. It is among the top undesirable events experienced by patients after anaesthesia. The supraglottic airway device (SAD) is commonly used as an airway device during the delivery of general anaesthesia. The incidence of POST after SAD use has been documented of up to 49% and is comparable with the incidence of up to 45% when using an endotracheal tube (ETT).
Many studies have been evaluating the occurrence of POST with the use of an ETT but studies investigating POST and the use of SAD are limited. A recent study comparing sore throat following three SADs (LMA™ Unique, LMA™ Supreme and I-gel®) found that the incidence of POST was not significantly different between any of them.
There are various drugs being extensively investigated to reduce the incidence and severity of POST such as Lignocaine, Dexamethasone, NSAIDs, Liquorice and NMDA receptor antagonists [1]. A Cochrane review on the use of Lignocaine for endotracheal intubation concluded that Lignocaine applied topically or administered systemically resulted in reduced risk and severity of POST.
Amylmetacresol and Dichlorobenzyl Alcohol, the active ingredient in the standard preparation of Strepsils® lozenges has been shown to reduce the intensity of sore throat in non-anaesthetised subjects, including one study involving Strepsils® Max Plus lozenges which additionally contains Lignocaine, a local anaesthetic agent. Currently studies that evaluated POST after endotracheal intubation using the standard preparation of Strepsils® (without Lignocaine) have reported a reduction in the incidence and severity of POST.
The effect of Strepsils® Max Plus (with Lignocaine) lozenges on POST and particularly due to SAD is not known and is the basis of this study. It is the investigator's hypothesis that Strepsils® with added Lignocaine will reduce the incidence and severity of POST based on existing studies that showed the individual and combined beneficial effect of both substances.
The goal of this study is to identify a simple, safe, and inexpensive perioperative intervention to reduce the incidence and severity of post operative sore throat due to supraglottic airway devices.
Eligible participants include adult patients scheduled to undergo elective surgery under general anaesthesia using a supraglottic airway device. This study is a prospective, randomised, double-blinded study involving 60 subjects and they will assessed on the incidence and severity of sore throat, dysphagia and dysphonia at 30 minutes and 24 hours after removal of the supraglottic airway device using an interview format.
Outcomes from this study can be extended to patients who will be receiving general anaesthesia using a supraglottic airway device in the future.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sore Throat, Post Operative Sore Throat
Keywords
Post operative sore throat, Post operative dysphagia, Post operative dysphonia
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
88 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Strepsils
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Strepsils Anaesthetic Formula
Other Intervention Name(s)
Strepsils Max Plus
Intervention Description
Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg with sweeteners and flavourings.
Intervention Type
Dietary Supplement
Intervention Name(s)
Clear Mint Drops
Intervention Description
Oral administration of a lozenge containing glucose syrup, sugar, and flavourings
Primary Outcome Measure Information:
Title
Incidence of sore throat
Description
Presence of sore throat defined as constant pain, independent of swallowing
Time Frame
30 minutes after the removal of Supraglottic Airway Device
Title
Incidence of sore throat
Description
Presence of sore throat defined as constant pain, independent of swallowing
Time Frame
24 hours after the removal of Supraglottic Airway Device
Secondary Outcome Measure Information:
Title
Severity of sorethroat
Description
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Time Frame
30 minutes after the removal of Supraglottic Airway Device
Title
Severity of sorethroat
Description
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Time Frame
24 hours after the removal of Supraglottic Airway Device
Title
Incidence of dysphagia
Description
Presence of dysphagia defined as difficulty or pain provoked by swallowing
Time Frame
30 minutes after the removal of Supraglottic Airway Device
Title
Incidence of dysphagia
Description
Presence of dysphagia defined as difficulty or pain provoked by swallowing
Time Frame
24 hours after the removal of Supraglottic Airway Device
Title
Incidence of dysphonia
Description
Presence of dysphonia defined as difficulty or pain on speaking
Time Frame
30 minutes after the removal of Supraglottic Airway Device
Title
Incidence of dysphonia
Description
Presence of dysphonia defined as difficulty or pain on speaking
Time Frame
24 hours after the removal of Supraglottic Airway Device
Title
Severity of dysphagia
Description
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Time Frame
30 minutes after the removal of Supraglottic Airway Device
Title
Severity of dysphagia
Description
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Time Frame
24 hours after the removal of Supraglottic Airway Device
Title
Severity of dysphonia
Description
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Time Frame
30 minutes after the removal of Supraglottic Airway Device
Title
Severity of dysphonia
Description
Severity will be graded by the patient as 0=null; 1=mild; 2=moderate; 3=severe
Time Frame
24 hours after the removal of Supraglottic Airway Device
Title
Adverse effects of study drug
Description
Any untoward medical occurrence in a subject administered an investigational product and which does not necessarily have a causal relationship with treatment.
Time Frame
30 minutes after the removal of Supraglottic Airway Device
Title
Adverse effects of study drug
Description
Any untoward medical occurrence in a subject administered an investigational product and which does not necessarily have a causal relationship with treatment.
Time Frame
24 hours after the removal of Supraglottic Airway Device
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Greater than 18 years of age
American Society of Anesthesiologists Class I-II
Supraglottic Airway Device usage duration < 2 hours
Exclusion Criteria:
History of upper respiratory tract infection, sore throat, dysphonia, or dysphagia in the past 2 weeks
Morbidly obese (body mass index >35 kg/m2)
Increased risk of regurgitation or aspiration (eg. symptomatic gastro-oesophageal reflux, hiatus hernia)
Pregnant or nursing
Known allergies to study drug
More than one attempt at Supraglottic Airway Device insertion or use of adjuncts during insertion
Insertion/presence of a gastric tube
Expected airway difficulties or conversion to endotracheal tube
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sebastian Sundaraj, MD
Organizational Affiliation
University Malaya
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Malaya Medical Centre
City
Kuala Lumpur
State/Province
Federal Territory Of Kuala Lumpur
ZIP/Postal Code
50603
Country
Malaysia
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
27158989
Citation
El-Boghdadly K, Bailey CR, Wiles MD. Postoperative sore throat: a systematic review. Anaesthesia. 2016 Jun;71(6):706-17. doi: 10.1111/anae.13438. Epub 2016 Mar 28.
Results Reference
background
PubMed Identifier
10475299
Citation
Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999 Sep;89(3):652-8. doi: 10.1097/00000539-199909000-00022.
Results Reference
background
PubMed Identifier
12066737
Citation
Higgins PP, Chung F, Mezei G. Postoperative sore throat after ambulatory surgery. Br J Anaesth. 2002 Apr;88(4):582-4. doi: 10.1093/bja/88.4.582.
Results Reference
background
PubMed Identifier
24097301
Citation
Wong DT, Tam AD, Mehta V, Raveendran R, Riad W, Chung FF. New supraglottic airway with built-in pressure indicator decreases postoperative pharyngolaryngeal symptoms: a randomized controlled trial. Can J Anaesth. 2013 Dec;60(12):1197-203. doi: 10.1007/s12630-013-0044-2. Epub 2013 Oct 5.
Results Reference
background
PubMed Identifier
27755181
Citation
L'Hermite J, Dubout E, Bouvet S, Bracoud LH, Cuvillon P, Coussaye JE, Ripart J. Sore throat following three adult supraglottic airway devices: A randomised controlled trial. Eur J Anaesthesiol. 2017 Jul;34(7):417-424. doi: 10.1097/EJA.0000000000000539.
Results Reference
background
PubMed Identifier
26171894
Citation
Tanaka Y, Nakayama T, Nishimori M, Tsujimura Y, Kawaguchi M, Sato Y. Lidocaine for preventing postoperative sore throat. Cochrane Database Syst Rev. 2015 Jul 14;2015(7):CD004081. doi: 10.1002/14651858.CD004081.pub3.
Results Reference
background
PubMed Identifier
28869700
Citation
Weckmann G, Hauptmann-Voss A, Baumeister SE, Klotzer C, Chenot JF. Efficacy of AMC/DCBA lozenges for sore throat: A systematic review and meta-analysis. Int J Clin Pract. 2017 Oct;71(10). doi: 10.1111/ijcp.13002. Epub 2017 Sep 4.
Results Reference
background
PubMed Identifier
20142339
Citation
Ebneshahidi A, Mohseni M. Strepsils(R) tablets reduce sore throat and hoarseness after tracheal intubation. Anesth Analg. 2010 Oct;111(4):892-4. doi: 10.1213/ANE.0b013e3181d00c60. Epub 2010 Feb 8.
Results Reference
background
PubMed Identifier
24843341
Citation
Gupta D, Agrawal S, Sharma JP. Evaluation of preoperative Strepsils lozenges on incidence of postextubation cough and sore throat in smokers undergoing anesthesia with endotracheal intubation. Saudi J Anaesth. 2014 Apr;8(2):244-8. doi: 10.4103/1658-354X.130737.
Results Reference
background
PubMed Identifier
21712716
Citation
Smith I, Kranke P, Murat I, Smith A, O'Sullivan G, Soreide E, Spies C, in't Veld B; European Society of Anaesthesiology. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2011 Aug;28(8):556-69. doi: 10.1097/EJA.0b013e3283495ba1.
Results Reference
background
PubMed Identifier
25442242
Citation
Ouanes JP, Bicket MC, Togioka B, Tomas VG, Wu CL, Murphy JD. The role of perioperative chewing gum on gastric fluid volume and gastric pH: a meta-analysis. J Clin Anesth. 2015 Mar;27(2):146-52. doi: 10.1016/j.jclinane.2014.07.005. Epub 2014 Nov 28.
Results Reference
background
PubMed Identifier
29077816
Citation
Bouvet L, Loubradou E, Desgranges FP, Chassard D. Effect of gum chewing on gastric volume and emptying: a prospective randomized crossover study. Br J Anaesth. 2017 Nov 1;119(5):928-933. doi: 10.1093/bja/aex270.
Results Reference
background
PubMed Identifier
26539790
Citation
Timmermann A, Bergner UA, Russo SG. Laryngeal mask airway indications: new frontiers for second-generation supraglottic airways. Curr Opin Anaesthesiol. 2015 Dec;28(6):717-26. doi: 10.1097/ACO.0000000000000262.
Results Reference
background
Learn more about this trial
Does Strepsils® With Lignocaine Lozenges Reduce Post Operative Sore Throat Due To Supraglottic Airway Devices
We'll reach out to this number within 24 hrs